To read the full version of this content please select one of the options below:

India’s key vaccine challenge is at home, not abroad

Thursday, November 25, 2021

Significance

Its vaccine production capacity has increased in the intervening period to the extent that it now has a surplus of doses, even allowing for supplies abroad. A key reason why so many doses are unused is that the domestic roll-out is stagnating.

Impacts

  • India’s COVID-19 vaccine portfolio will diversify markedly.
  • Russian vaccines made in India will mainly be exported, due to low domestic demand.
  • Delhi may begin rolling out coronavirus booster vaccines for high-priority groups early next year.
Expert Briefings Powered by Oxford Analytica
Stay up to date
Sign up to the Expert Daily Briefings email alert and receive up-to-the-minute analysis of global events as they happen.
*If your university does not have access to Expert Briefings, visit our information page to find out more.